

1 The Omega-3 Index is Inversely Associated with the Neutrophil-Lymphocyte Ratio in Adults

2 Michael I. McBurney¹⁻³, Nathan L. Tintle^{1,4}, William S. Harris^{1,5}

3 ¹Fatty Acid Research Institute, Sioux Falls, SD 57106, USA (MIM, NLT, WSH); ²Department of
4 Human Health and Nutritional Sciences, University of Guelph, Guelph, ON N1G 2W1, Canada
5 (MIM), ³Division of Biochemical and Molecular Biology, Friedman School of Nutrition Science
6 and Policy, Tufts University, Boston, MA 02111, USA (MIM); ⁴Department of Population Health
7 Nursing Science, College of Nursing, University of Illinois – Chicago, Chicago, IL 60612,
8 USA(NLT); ⁵Sanford School of Medicine, University of South Dakota, Sioux Falls, SD 57105, USA
9 (WSH).

10

11 **Authors last names:** McBurney, Tintle, Harris

12

13 **Corresponding author:** M.I. McBurney, Fatty Acid Research Institute, Sioux Falls, SD 57106,
14 USA. E-mail: mim@faresinst.com

15

16 **Reprint requests:** W.S. Harris, Fatty Acid Research Institute, Sioux Falls, SD 57106, USA. E-mail:
17 wsh@faresinst.com

18

19 **Sources of Support:** This work was supported by the Fatty Acid Research Institute (FARI). FARI is
20 a non-profit foundation bringing together nutrition scientists and biostatistical experts to
21 accelerate discovery of the relationships between fatty acids, especially omega-3 fatty acids,
22 and health. Pending application and approval, data described in the manuscript, code book, and
23 analytic code will be made available upon request to the Fatty Acid Research Institute
24 (<https://www.faresinst.org/>).

25

26 **Summary**

27 The neutrophil-lymphocyte ratio (NLR) is a biomarker of systemic inflammation and measures
28 innate-adaptive immune system balance. The omega-3-index (O3I) measures the amount of
29 EPA+DHA in blood. Both a low O3I and an elevated NLR are associated with increased risk for
30 chronic disease and mortality, including cardiovascular diseases and cancer. Hypothesizing that
31 low O3I may partly contribute to systemic chronic inflammation, we asked if a relationship
32 existed between O3I and NLR in healthy adults (≥ 18 y, $n=28,871$, 51% female) without
33 inflammation [C-reactive protein (CRP) < 3 mg/mL] who underwent a routine clinical
34 assessment. NLR was inversely associated with O3I before ($p < 0.0001$) and after adjusting for
35 age, sex, BMI, and CRP ($p < 0.0001$). Pearson correlations of other variables with NLR were
36 $r=0.06$ (CRP), $r=0.14$ (age), and $r=0.01$ (BMI). In this healthy population, an O3I $< 6.6\%$ was
37 associated with increasing NLR whereas NLR remained relatively constant (low) when O3I
38 $> 6.6\%$, suggestive of a quiescent, balanced immune system.

39

40 **Keywords:** neutrophils, lymphocytes, neutrophil-lymphocyte ratio, omega-3 index,

41 eicosapentaenoic acid, docosahexaenoic acid

42

43 **Abbreviations:** BMI, body mass index; CRP, high-sensitivity C-reactive protein; DHA,

44 docosahexaenoic acid; EPA, eicosapentaenoic acid; NLR, neutrophil-lymphocyte ratio; O3I,

45 omega-3 index; SPM, specialized pro-resolving lipid mediators.

46

47 **1. Introduction**

48 Cells from both the innate and adaptive immune system circulate in blood. Cells of the
49 former (i.e., neutrophils, phagocytes, dendritic cells, macrophages, eosinophils, basophils, mast
50 cells, and natural killer cells) work together to neutralize pathogens, in part by releasing pro-
51 inflammatory mediators that modulate the latter. Neutrophils are the most abundant
52 leukocytes in circulation. They migrate to sites of tissue injury or damage and are responsible
53 for a non-specific inflammatory response. The adaptive system (acquired immunity) responds
54 to specific pathogens and cytokines by producing antibodies and maintains immunological
55 memory via lymphocytes, i.e., T and B cells. The hallmark of the adaptive immune system is
56 clonal expansion of lymphocytes. Inflammation is generally self-limiting, with its resolution
57 being an active rather than passive process [1]. Chronic or unresolved inflammation can
58 damage host tissues and increase risk for the development of a range of non-communicable
59 diseases, e.g. cardiovascular, cancer, chronic respiratory diseases, diabetes, and autoimmune
60 disorders, e.g. rheumatoid arthritis [2–4].

61 The neutrophil-lymphocyte ratio (NLR) is an emerging biomarker of systemic inflammation
62 [5–8] and innate-adaptive immune system balance [6,9] that is readily accessible from a
63 complete blood count. It has the benefit of not being influenced by physiological conditions
64 such as dehydration and exercise [6]. NLR has been used to monitor astronaut immune function
65 during long-duration missions [10]. Elevated NLR is also a biomarker of systemic inflammation
66 [5,11–14], cardiovascular disease and events [6,15–18], the severity of covid-19 [19–22], mood
67 disorders [23], cognitive impairment [24], cancer [6,7,25], dry eye [26], periodontitis [27],

68 rheumatoid arthritis [28], cancer [12,25,29], diabetic kidney disease [30] and total mortality
69 [6,9,14,17,31,32].

70 Nutrient deficiencies or inadequacies can impair immune system function and weaken the
71 immune response [3,33–36]. The proportion of EPA and DHA in immune cell membranes can
72 modulate inflammation via the synthesis of prostaglandins, leukotrienes, lipoxins and
73 specialized pro-resolving lipid mediators (SPMs, e.g., resolvins, protectins, and maresins) [1,37].
74 The EPA and DHA-derived metabolites are less inflammatory than those derived from the
75 omega-6 precursor, arachidonic acid [1,33,37–42]. SPMs derived from EPA and DHA reduce
76 neutrophil infiltration and production of reactive oxygen species, regulate the cytokine-
77 chemokine axis, and temper the inflammatory response without immunosuppression [37,43–
78 45]. The omega-3 index (O3I) [46] is a stable biomarker of long term EPA and DHA intake
79 [47,48]. A low O3I [49] and an elevated NLR [14,18,50] are both associated with risk of
80 cardiovascular events and mortality (**Supplemental Table 1**). Hypothesizing that low blood
81 EPA+DHA levels may partly contribute to systemic chronic inflammation, we asked if there was
82 a relationship between the O3I and the NLR in healthy individuals without inflammation.

83 **2. Patients and Methods**

84 This is a cross-sectional analysis of data from blood samples submitted for testing to
85 Health Diagnostic Laboratory, Inc (HDL, Inc., Richmond VA; now defunct) as part of routine
86 clinical assessment between 2011-2012. Subjects were adults (≥ 18 y) with data on O3I, NLR,
87 body mass index (BMI), age, sex, and high-sensitivity C-reactive protein (CRP) (n=44,925).
88 Individuals with extreme O3I values (i.e., highest and lowest 0.5%) were excluded. Because CRP
89 > 3 mg/L is indicative of inflammation arising from infection, trauma or chronic disease [51–54],

90 individuals with CRP >3 mg/L were also excluded. Thus, the final study population consisted of
91 28,871 individuals (**Figure 1**).

92 *2.1 Laboratory Methods*

93 Blood samples were drawn after an overnight fast and shipped with cold packs to HDL, Inc.
94 for testing. Samples were prepared at each clinical site according to standardized instructions
95 as previously described [55]. Absolute concentrations of blood cells (neutrophils, lymphocytes,
96 NLR) were determined with a Beckman-Coulter DxH 800 analyzer (Brea, CA, USA) and
97 biomarker data (CRP, O3I) were extracted without any linked patient identifiers except age, sex,
98 and BMI. For fatty acid analysis, RBCs were separated from plasma by centrifugation and
99 analyzed using gas chromatography as previously described [56]. The University of South
100 Dakota Institutional Review Board reviewed and approved the use of such de-identified clinical
101 data for research purposes (IRB-21-147).

102

103 *2.2 Statistical methods*

104 Sample characteristics were summarized using standard statistical methods (e.g., means,
105 SDs, correlations) with t-tests and adjusted linear models used to compare characteristics of
106 male and female participants above and below O3I values that were ultimately identified as
107 primary cut points in the NLR-O3I curves (see below). Splines were fit using 3rd degree
108 polynomials with knots at each decile in R (version 3.6.2; splines package). Unadjusted models
109 used a linear model to predict NLR values by splines of O3I. Adjusted models accounted for sex,
110 age, BMI and CRP values in the linear models accounting for potential non-linear relationships
111 using splines. To identify significant changes in the NLR-O3I relationship, we used a “sliding O3I

112 window” approach. The width of each window was three O3I percentage points (e.g., 4% to
113 7%). By moving the window up by 0.1% increments and repeatedly testing for significant
114 differences between the mean NLR in the lower vs. the upper half of the window, we sought to
115 discover O3I cut points where the NLR-O3I relationship appeared to flatten. These would be O3I
116 values above which the “effect” of an increase in O3I on NLR had little impact. We began with a
117 window midpoint of O3I =2.6%, and we used adjusted linear models in R to test for upper vs
118 lower half differences. We identified the first window which did not have a statistically
119 significant difference in upper and lower mean NLR values. The midpoint of this window was
120 chosen as the O3I cut point to be used in further analysis.

121 Statistical interactions with O3I values above and below the subsequently identified
122 inflection points were tested by placing the interaction term in separate models predicting O3I,
123 NLR, age, sex, BMI, and CRP. Pearson correlations were used to assess strength and direction of
124 linear association between covariates and NLR. Statistical significance was set to 0.05 for all
125 analyses and 95% confidence bands are provided where appropriate.

126 **3. Results**

127 The final dataset consisted of 28,871 healthy adults (**Figure 1**). The average age was
128 55.1 ± 15.1 years, the average BMI was 27.6 ± 5.4 kg/m², and there were slightly more females
129 (51%) than males. Females were significantly younger and had slightly but significantly higher
130 O3I and CRP levels and lower NLR, neutrophil count, and BMI than males (**Table 1**). When the
131 model was also adjusted for age, BMI and CRP, small but significant sex differences remained
132 with the exception of BMI (**Table 1**).

133 NLR was significantly ($p < 0.0001$) and inversely associated with O3I (**Figure 2A**). Pearson
134 correlations (r) of other variables with NLR were $r = 0.06$ (CRP), $r = 0.14$ (age), $r = 0.01$ (BMI), $r = 0.65$
135 (neutrophil count), and $r = -0.24$ (lymphocyte count). Adjustment for age, sex, BMI, and CRP
136 strengthened the relationship (**Figure 2B**). The O3I value where the relationship between O3I
137 and NLR began to flatten (i.e., the cut point determined by the sliding window analysis
138 described in Methods) was 6.6% although NLR continued to decline until O3I $> 8.5\%$ (**Figure 2B**).
139 Below 6.6%, the curve was clearly steeper than it was above 6.6%. The O3I cut point of 6.6%
140 was explored in more detail. An O3I $< 6.6\%$ was associated with significantly higher NLR,
141 neutrophil number, lymphocyte number, CRP, BMI, and lower age (versus O3I $\geq 6.6\%$) (**Table 2**).
142 These O3I-related differences persisted, except for lymphocyte number, when the model was
143 adjusted for age, sex, BMI and CRP (**Table 2**).

144 When adults with inflammation (CRP > 3 mg/L) were included ($n = 43,851$), NLR was
145 significantly and inversely related with O3I before ($p < 0.0001$) and after adjusting for age, sex,
146 BMI and CRP ($p < 0.0001$) (**Supplemental Figure 1**). As noted above, we chose to restrict our
147 analysis to a healthy population (i.e., without evident inflammation) to establish EPA+DHA
148 standards that could be used to develop DRIs.

149 **4. Discussion and Conclusions**

150 We report a significant inverse relationship between O3I and NLR. By excluding individuals
151 with CRP > 3 mg/L, we could examine the O3I-NLR relationship in individuals without any
152 evidence of tissue injury, infection, or systemic acute inflammation [57,58], i.e. a cohort
153 suitable for deriving O3I standards on which Dietary Reference Intakes (DRIs) could be
154 developed for planning and assessing EPA+DHA intakes of healthy people. NLR values measured

155 in this cohort (**Table 1**) were similar to those measured in healthy adults globally [8,24,59–63].
156 NLR is known to increase with age [9,32,60], obesity [13,60], CRP [64,65], and to sometimes
157 differ by sex [32,59]. These same relationships were mostly observed here as well (data not
158 reported), suggesting that the findings from this clinical laboratory cohort are generally
159 representative.

160 Inflammation is a normal physiological response to infection and injury, but unrestrained
161 inflammation can cause tissue damage leading to disease. As noted earlier, EPA and DHA serve
162 as precursors for the synthesis of prostaglandins, leukotrienes, lipoxins and SPMs that can
163 mediate immune responses [1,29,33,37,39–41]. SPMs derived from EPA and DHA protect
164 tissues by limiting acute inflammatory responses and helping achieve homeostasis without
165 immunosuppression [37,44,45]. In a randomized, double-blind, crossover trial,
166 supplementation (10wk) with high doses of EPA or DHA (~8g/d) in individuals with abdominal
167 obesity and low-grade inflammation (baseline CRP 3.3 ± 2.4 mg/L) separated by a 9-wk washout
168 significantly increased blood EPA and DHA concentrations (vs corn oil control) [66]. DHA, but
169 not EPA, supplementation decreased CRP concentrations (vs control) and the authors
170 concluded EPA and DHA had more consistent effects on anti-inflammatory gene expression
171 than pro-inflammatory gene expression [66]. Using pairwise and network meta-analyses of
172 randomized controlled trials, DHA and EPA seem to have similar effects on CRP, IL-6, TNF- α , and
173 adiponectin [67]. Although EPA and DHA trigger anti-inflammatory responses in vitro [68,69],
174 the effects of long-chain omega-3 fatty acids on plasma CRP concentrations are mixed [70–73].
175 A threshold blood EPA+DHA concentration may be required to fuel sufficient SPM biosynthesis
176 to achieve meaningful resolution of inflammation [37].

177 Omega-3 supplementation increases the EPA+DHA content of neutrophil membranes in
178 vivo and inhibits the 5-lipoxygenase pathway and leukotriene B₄-mediated functions of
179 neutrophils *in vitro* [38]. Omega-3 supplementation significantly increased plasma EPA+DHA
180 levels (50-100%) and decreased concentrations of IL-6 (10-12% vs 36% increase in placebo
181 group) and TNF α (0.2 to -2.3% vs 12% increase in placebo group) in healthy, middle-aged and
182 older individuals [74]. Meta-analyses have confirmed this effect [72]. In a study of 8,237
183 participants living in Japan without a history of cardiovascular disease, eating fish >4 days per
184 week was associated with significant lower NLR [75]. High omega-3 dietary intake was
185 associated with a trend towards lower CRP (p=0.09) and NLR (p=0.17) in men with acute
186 coronary syndrome [76]. A systematic review and meta-analysis of 18 randomized controlled
187 trials found marine-derived omega-3 fatty acids lowered pro-inflammatory eicosanoid
188 concentrations, e.g., in neutrophil leukotriene B₄ [77]. In the long-term, chronically lower levels
189 of inflammation may have health benefits. For example, a pooled analysis of data from 17
190 prospective cohort studies involving 15,720 deaths among 43,466 individuals over a median of
191 16 years of follow-up found blood EPA+DHA levels were inversely associated with risk for death
192 from all causes, CVD, cancer and other causes [49].

193 Despite the strength of the NLR-O3I relationship, the most obvious limitation of this study
194 is that confounding metabolic events, dietary behaviors, smoking habits and/or physical activity
195 levels associated with O3I may also affect innate-adaptive immune system balance. However, a
196 nationally representative study of 9,427 individuals living in the US did not find significant
197 differences in NLR with respect to sex, education, insurance status, or drinking habits [59].
198 Moreover, this cross-sectional population is similar to 2/3 of the US population who have CRP

199 <3mg/L [78] and the ~95% of adults living in the USA with circulating O3I percentages below 5%
200 [79,80].

201 In this cross-sectional study of healthy individuals, 81% of participants had O3I <6.6%.
202 Below this threshold, an increase in NLR, reflecting an increasingly imbalanced innate-adaptive
203 immune system, was observed. NLR continued to decrease with increasing O3I until O3I >8.5%,
204 similar to the target proposed for cardiovascular health, i.e. O3I >8% [46,81]. Clearly additional
205 evidence, including intervention studies, is needed to determine whether the NLR-O3I
206 relationship is causal or coincidental.

207 In conclusion, red blood cell EPA+DHA levels are significantly and inversely associated with
208 NLR, a biomarker of inflammation and innate-adaptive immune system balance. Based on our
209 observations in this healthy cohort, an O3I >6.6%, and possibly as high as 8.5%, is associated
210 with lower NLR values that are indicative of a quiescent, balanced innate-adaptive immune
211 system.

212

213 **Acknowledgements:** The authors wish to thank Steven Varvel, PhD for his help in acquiring and
214 collating the dataset used in this study.

215 **CReditT authorship contribution statement:** **M.I. McBurney:** Conceptualization & analytical
216 design. Writing -original draft, review & editing. **W.S. Harris:** Conceptualization & analytical
217 design. Funding acquisition. Writing- review & editing. **N.L. Tintle:** Formal analysis. Writing-
218 review & editing.

219 **Disclosures:** M.I. McBurney serves on the Board of Directors of the American Society for
220 Nutrition and has or has held consulting agreements in the past 3 years with Council for
221 Responsible Nutrition; Church & Dwight; DSM Nutritional Products; International Life Sciences
222 Institute, North America; McCormick; OmegaQuant Analytics; PepsiCo; and VitaMe
223 Technologies. W.S. Harris holds an interest in OmegaQuant Analytics, a lab that offers omega-3
224 blood testing; and is a member of the RB Schiff Science and Innovation Advisory Board. N.L.
225 Tintle has no conflicts to disclose.

226

227 **References**

- 228 [1] C.N. Serhan, Pro-resolving lipid mediators are leads for resolution physiology, *Nature*. 510
229 (2014) 92–101. <https://doi.org/10.1038/nature13479>.
- 230 [2] P.C. Calder, Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms
231 and clinical relevance, *Bioch. Biophys. Acta: Mol Cell Biol Lipids*. 1851 (2015) 469–484.
232 <https://doi.org/10.1016/j.bbalip.2014.08.010>.
- 233 [3] Childs, Calder, Miles, Diet and Immune Function, *Nutrients*. 11 (2019) 1933.
234 <https://doi.org/10.3390/nu11081933>.
- 235 [4] D. Furman, J. Campisi, E. Verdin, P. Carrera-Bastos, S. Targ, C. Franceschi, L. Ferrucci, D.W.
236 Gilroy, A. Fasano, G.W. Miller, A.H. Miller, A. Mantovani, C.M. Weyand, N. Barzilai, J.J.
237 Goronzy, T.A. Rando, R.B. Effros, A. Lucia, N. Kleinstreuer, G.M. Slavich, Chronic
238 inflammation in the etiology of disease across the life span, *Nat Med*. 25 (2019) 1822–
239 1832. <https://doi.org/10.1038/s41591-019-0675-0>.
- 240 [5] F. Imtiaz, K. Shafique, S.S. Mirza, Z. Ayoob, P. Vart, S. Rao, Neutrophil lymphocyte ratio as a
241 measure of systemic inflammation in prevalent chronic diseases in Asian population,
242 *International Archives of Medicine*. 5 (2012) 2. <https://doi.org/10.1186/1755-7682-5-2>.
- 243 [6] T. Bhat, S. Teli, J. Rijal, H. Bhat, M. Raza, G. Khoueiry, M. Meghani, M. Akhtar, Neutrophil
244 to lymphocyte ratio and cardiovascular diseases: a review, *Expert Rev. Cardiovasc. Ther.*
245 (2013) 6.
- 246 [7] S. Socorro Faria, P.C. Fernandes Jr, M.J. Barbosa Silva, V.C. Lima, W. Fontes, R. Freitas-
247 Junior, A.K. Eterovic, P. Forget, The neutrophil-to-lymphocyte ratio: a narrative review,
248 *Ecancel*. 10 (2016). <https://doi.org/10.3332/ecancer.2016.702>.

- 249 [8] J. Fest, R. Ruiter, M.A. Ikram, T. Voortman, C.H.J. van Eijck, B.H. Stricker, Reference values
250 for white blood-cell-based inflammatory markers in the Rotterdam Study: a population-
251 based prospective cohort study, *Sci Rep.* 8 (2018) 10566. [https://doi.org/10.1038/s41598-](https://doi.org/10.1038/s41598-018-28646-w)
252 018-28646-w.
- 253 [9] M. Song, B.I. Graubard, C.S. Rabkin, E.A. Engels, Neutrophil-to-lymphocyte ratio and
254 mortality in the United States general population, *Nature Res.* 11 (2021) 464.
255 <https://doi.org/10.1038/s41598-020-79431-7>.
- 256 [10] A.M. Paul, S.D. Mhatre, E. Cekanaviciute, A.-S. Schreurs, C.G.T. Tahimic, R.K. Globus, S.
257 Anand, B.E. Crucian, S. Bhattacharya, Neutrophil-to-Lymphocyte Ratio: A Biomarker to
258 Monitor the Immune Status of Astronauts, *Front. Immunol.* 11 (2020) 564950.
259 <https://doi.org/10.3389/fimmu.2020.564950>.
- 260 [11] R. Zahorec, Ratio of neutrophil to lymphocyte counts - rapid and simple parameter of
261 systemic inflammation and stress in critically ill, *Bratisl. Lek. Listy.* 102 (2001) 5–14.
- 262 [12] L. Venkatraghavan, T.P. Tan, J. Mehta, A. Arekapudi, A. Govindarajulu, E. Siu, Neutrophil
263 Lymphocyte Ratio as a predictor of systemic inflammation - A cross-sectional study in a
264 pre-admission setting., *F1000Res.* 4 (2015) 123.
265 <https://doi.org/10.12688/f1000research.6474.1>.
- 266 [13] E. Rodríguez-Rodríguez, A.M. López-Sobaler, R.M. Ortega, M.L. Delgado-Losada, A.M.
267 López-Parra, A. Aparicio, Association between Neutrophil-to-Lymphocyte Ratio with
268 Abdominal Obesity and Healthy Eating Index in a Representative Older Spanish Population,
269 *Nutrients.* 12 (2020) 855. <https://doi.org/10.3390/nu12030855>.

- 270 [14] H. Wada, T. Dohi, K. Miyauchi, R. Nishio, M. Takeuchi, N. Takahashi, H. Endo, M. Ogita, H.
271 lwata, T. Kasai, S. Okazaki, K. Isoda, S. Suwa, H. Daida, Neutrophil to Lymphocyte Ratio and
272 Long-Term Cardiovascular Outcomes in Coronary Artery Disease Patients with Low High-
273 Sensitivity C-Reactive Protein Level, *Int. Heart J.* 61 (2020) 447–453.
274 <https://doi.org/10.1536/ihj.19-543>.
- 275 [15] B. Suh, D.W. Shin, H.-M. Kwon, J.M. Yun, H.-K. Yang, E. Ahn, H. Lee, J.H. Park, B. Cho,
276 Elevated neutrophil to lymphocyte ratio and ischemic stroke risk in generally healthy
277 adults, *PLoS ONE.* 12 (2017) e0183706. <https://doi.org/10.1371/journal.pone.0183706>.
- 278 [16] T. Angkananard, T. Anothaisintawee, M. McEvoy, J. Attia, A. Thakkinstian, Neutrophil
279 Lymphocyte Ratio and Cardiovascular Disease Risk: A Systematic Review and Meta-
280 Analysis, *BioMed Research International.* 2018 (2018) 1–11.
281 <https://doi.org/10.1155/2018/2703518>.
- 282 [17] N.H. Adamstein, J.G. MacFadyen, L.M. Rose, R.J. Glynn, A.K. Dey, P. Libby, I.A. Tabas, N.N.
283 Mehta, P.M. Ridker, The neutrophil–lymphocyte ratio and incident atherosclerotic events:
284 analyses from five contemporary randomized trials, *European Heart Journal.* 42 (2021)
285 896–903. <https://doi.org/10.1093/eurheartj/ehaa1034>.
- 286 [18] L. Zhan, Y. Liu, Y. Cheng, W. Guo, J. Yang, Predictive Value of Neutrophil/Lymphocyte Ratio
287 (NLR) on Cardiovascular Events in Patients with COVID-19, *IJGM.* Volume 14 (2021) 3899–
288 3907. <https://doi.org/10.2147/IJGM.S317380>.
- 289 [19] S. Qun, Y. Wang, J. Chen, X. Huang, H. Guo, Z. Lu, J. Wang, C. Zheng, Y. Ma, Y. Zhu, D. Xia,
290 Y. Wang, H. He, Y. Wang, M. Fei, Y. Yin, M. Zheng, Y. Xu, W. Ge, F. Hu, J. Zhou, Neutrophil-

- 291 to-Lymphocyte Ratios Are Closely Associated With the Severity and Course of Non-mild
292 COVID-19, *Front. Immunol.* 11 (2020) 2160. <https://doi.org/10.3389/fimmu.2020.02160>.
- 293 [20] S. Sun, X. Cai, H. Wang, G. He, Y. Lin, B. Lu, C. Chen, Y. Pan, X. Hu, Abnormalities of
294 peripheral blood system in patients with COVID-19 in Wenzhou, China, *Clinica Chimica*
295 *Acta.* 507 (2020) 174–180. <https://doi.org/10.1016/j.cca.2020.04.024>.
- 296 [21] M. Seyit, E. Avci, R. Nar, H. Senol, A. Yilmaz, M. Ozen, A. Oskay, H. Aybek, Neutrophil to
297 lymphocyte ratio, lymphocyte to monocyte ratio and platelet to lymphocyte ratio to
298 predict the severity of COVID-19, *The American Journal of Emergency Medicine.* 40 (2021)
299 110–114. <https://doi.org/10.1016/j.ajem.2020.11.058>.
- 300 [22] E. Vafadar Moradi, A. Teimouri, R. Rezaee, N. Morovatdar, M. Foroughian, P. Layegh, B.
301 Rezvani Kakhki, S.R. Ahmadi Koupaeei, V. Ghorani, Increased age, neutrophil-to-lymphocyte
302 ratio (NLR) and white blood cells count are associated with higher COVID-19 mortality, *The*
303 *American Journal of Emergency Medicine.* 40 (2021) 11–14.
304 <https://doi.org/10.1016/j.ajem.2020.12.003>.
- 305 [23] M.G. Mazza, S. Lucchi, A.G.M. Tringali, A. Rossetti, E.R. Botti, M. Clerici,
306 Neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in mood disorders: A meta-
307 analysis, *Progress in Neuro-Psychopharmacology and Biological Psychiatry.* 84 (2018) 229–
308 236. <https://doi.org/10.1016/j.pnpbp.2018.03.012>.
- 309 [24] J.-H. Liu, Y.-J. Zhang, Q.-H. Ma, H.-P. Sun, Y. Xu, C.-W. Pan, Elevated blood neutrophil to
310 lymphocyte ratio in older adults with cognitive impairment, *Archives of Gerontology and*
311 *Geriatrics.* 88 (2020) 104041. <https://doi.org/10.1016/j.archger.2020.104041>.

- 312 [25] A.J. Templeton, M.G. McNamara, B. Šeruga, F.E. Vera-Badillo, P. Aneja, A. Ocaña, R.
313 Leibowitz-Amit, G. Sonpavde, J.J. Knox, B. Tran, I.F. Tannock, E. Amir, Prognostic Role of
314 Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis,
315 JNCI: Journal of the National Cancer Institute. 106 (2014).
316 <https://doi.org/10.1093/jnci/dju124>.
- 317 [26] Y.-F. Meng, Q. Pu, Q. Ma, W. Zhu, X.-Y. Li, Neutrophil/lymphocyte ratio as an inflammatory
318 predictor of dry eye: A case-control study, Therapeutics and Clinical Risk Management. 17
319 (2021) 259–266.
- 320 [27] R. Lu, W. Li, X. Wang, D. Shi, H. Meng, Elevated neutrophil-to-lymphocyte ratio but not
321 platelet-to-lymphocyte ratio is associated with generalized aggressive periodontitis in a
322 Chinese population, J Periodontol. 92 (2021) 507–513. [https://doi.org/10.1002/JPER.20-](https://doi.org/10.1002/JPER.20-0282)
323 0282.
- 324 [28] Z. Jin, G. Cai, P. Zhang, X. Li, S. Yao, L. Zhuang, M. Ren, Q. Wang, X. Yu, The value of the
325 neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as complementary
326 diagnostic tools in the diagnosis of rheumatoid arthritis: A multicenter retrospective study,
327 J Clin Lab Anal. 35 (2021). <https://doi.org/10.1002/jcla.23569>.
- 328 [29] L. Xia, W. Li, J. Zhai, C. Yan, J. Chen, H. Yang, Significance of neutrophil-to-lymphocyte
329 ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio and prognostic
330 nutritional index for predicting clinical outcomes in T1–2 rectal cancer, BMC Cancer. 20
331 (2020) 208. <https://doi.org/10.1186/s12885-020-6698-6>.

- 332 [30] L. Winter, L.A. Wong, G. Jerums, J. Seah, M. Clarke, S.M. Tan, M.T. Coughlan, R.J. Maclsaac,
333 E.I. Ekinci, Use of Readily Accessible Inflammatory Markers to Predict Diabetic Kidney
334 Disease, *Front. Endocrinol.* 9 (2018) 225. <https://doi.org/10.3389/fendo.2018.00225>.
- 335 [31] S. Balta, S. Demirkol, M. Unlu, Z. Arslan, T. Celik, Neutrophil to lymphocyte ratio may be
336 predict of mortality in all conditions, *Br J Cancer.* 109 (2013) 3125–3126.
337 <https://doi.org/10.1038/bjc.2013.598>.
- 338 [32] J. Fest, T.R. Ruiters, B. Groot Koerkamp, D. Rizopoulos, M.A. Ikram, C.H.J. van Eijck, B.H.
339 Stricker, The neutrophil-to-lymphocyte ratio is associated with mortality in the general
340 population: The Rotterdam Study, *Eur J Epidemiol.* 34 (2019) 463–470.
341 <https://doi.org/10.1007/s10654-018-0472-y>.
- 342 [33] D. Wu, E.D. Lewis, M. Pae, S.N. Meydani, Nutritional Modulation of Immune Function:
343 Analysis of Evidence, Mechanisms, and Clinical Relevance, *Front. Immunol.* 9 (2019) 3160.
344 <https://doi.org/10.3389/fimmu.2018.03160>.
- 345 [34] P.C. Calder, A.C. Carr, A.F. Gombart, M. Eggersdorfer, Optimal Nutritional Status for a
346 Well-Functioning Immune System Is an Important Factor to Protect against Viral
347 Infections, *Nutrients.* 12 (2020) 1181. <https://doi.org/10.3390/nu12041181>.
- 348 [35] A.F. Gombart, A. Pierre, S. Maggini, A Review of Micronutrients and the Immune System—
349 Working in Harmony to Reduce the Risk of Infection, *Nutrients.* 12 (2020) 236.
350 <https://doi.org/10.3390/nu12010236>.
- 351 [36] C.A. Reider, R.-Y. Chung, P.P. Devarshi, R.W. Grant, S. Hazels Mitmesser, Inadequacy of
352 Immune Health Nutrients: Intakes in US Adults, the 2005–2016 NHANES, *Nutrients.* 12
353 (2020) 1735. <https://doi.org/10.3390/nu12061735>.

- 354 [37] P.C. Calder, Eicosapentaenoic and docosahexaenoic acid derived specialised pro-resolving
355 mediators: Concentrations in humans and the effects of age, sex, disease and increased
356 omega-3 fatty acid intake, *Biochimie*. 178 (2020) 105–123.
357 <https://doi.org/10.1016/j.biochi.2020.08.015>.
- 358 [38] T.H. Lee, R.L. Hoover, J.D. Williams, R.I. Sperling, J. Ravalese III, B.W. Spur, D.R. Robinson,
359 E.J. Corey, R.A. Lewis, K.F. Austen, Effect of dietary enrichment with eicosapentaenoic acid
360 and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation
361 and neutrophil function, *New England Journal of Medicine*. 312 (1985) 217–224.
- 362 [39] P. Yaqoob, P.C. Calder, Fatty acids and immune function: new insights into mechanisms, *Br*
363 *J Nutr*. 98 (2007) S41–S45. <https://doi.org/10.1017/S0007114507832995>.
- 364 [40] E.A. Dennis, P.C. Norris, Eicosanoid storm in infection and inflammation, *Nat Rev Immunol*.
365 15 (2015) 511–523. <https://doi.org/10.1038/nri3859>.
- 366 [41] U. Radzikowska, A.O. Rinaldi, Z. Çelebi Sözener, D. Karaguzel, M. Wojcik, K. Cypryk, M.
367 Akdis, C.A. Akdis, M. Sokolowska, The Influence of Dietary Fatty Acids on Immune
368 Responses, *Nutrients*. 11 (2019) 2990. <https://doi.org/10.3390/nu11122990>.
- 369 [42] J. McDaniel, Regulation of Neutrophil Function by Marine n-3 Fatty Acids—A Mini Review,
370 *Cell Biochem Biophys*. (2021). <https://doi.org/10.1007/s12013-021-01001-z>.
- 371 [43] C.N. Serhan, N. Chiang, T.E. Van Dyke, Resolving inflammation: dual anti-inflammatory and
372 pro-resolution lipid mediators, *Nat Rev Immunol*. 8 (2008) 349–361.
373 <https://doi.org/10.1038/nri2294>.

- 374 [44] J. Dalli, J.W. Winkler, R.A. Colas, H. Arnardottir, C.-Y.C. Cheng, N. Chiang, N.A. Petasis, C.N.
375 Serhan, Resolvin D3 and Aspirin-Triggered Resolvin D3 Are Potent Immunoresolvents,
376 Chemistry & Biology. 20 (2013) 188–201. <https://doi.org/10.1016/j.chembiol.2012.11.010>.
- 377 [45] J.K. Colby, R.-E.E. Abdunour, H.P. Sham, J. Dalli, R.A. Colas, J.W. Winkler, J. Hellmann, B.
378 Wong, Y. Cui, S. El-Chemaly, N.A. Petasis, M. Spite, C.N. Serhan, B.D. Levy, Resolvin D3 and
379 Aspirin-Triggered Resolvin D3 Are Protective for Injured Epithelia, The American Journal of
380 Pathology. 186 (2016) 1801–1813. <https://doi.org/10.1016/j.ajpath.2016.03.011>.
- 381 [46] W.S. Harris, C. von Schacky, The Omega-3 Index: a new risk factor for death from coronary
382 heart disease?, Prev. Med. 39 (2004) 212–220.
383 <https://doi.org/10.1016/j.ypmed.2004.02.030>.
- 384 [47] M.R. Flock, A.C. Skulas-Ray, W.S. Harris, T.D. Etherton, J.A. Fleming, P.M. Kris-Etherton,
385 Determinants of erythrocyte omega-3 fatty acid content in response to fish oil
386 supplementation: A dose–response randomized controlled trial, J. Am. Heart Assoc. 2
387 (2013) e000513. <https://doi.org/10.1161/JAHA.113.000513>.
- 388 [48] R.E. Walker, K.H. Jackson, N.L. Tintle, G.C. Shearer, A. Bernasconi, S. Masson, R. Latini, B.
389 Heydari, R.Y. Kwong, M. Flock, P.M. Kris-Etherton, A. Hedengran, R.M. Carney, A. Skulas-
390 Ray, S.S. Gidding, A. Dewell, C.D. Gardner, S.M. Grenon, B. Sarter, J.W. Newman, T.L.
391 Pedersen, M.K. Larson, W.S. Harris, Predicting the effects of supplemental EPA and DHA
392 on the omega-3 index, Am. J. Clin. Nutr. 110 (2019) 1034–1040.
393 <https://doi.org/10.1093/ajcn/nqz161>.
- 394 [49] W.S. Harris, N.L. Tintle, F. Imamura, F. Qian, A.V. Ardisson Korat, M. Marklund, L. Djoussé,
395 J.K. Bassett, P.-H. Carmichael, Y.-Y. Chen, Y. Hirakawa, L.K. Kupers, M. Lankinen, R.A.

- 396 Murphy, C. Samieri, M.K. Senn, P. Shi, J.K. Virtanen, I.A. Brouwer, K.-L. Chien, G.
397 Eiriksdottir, N.G. Forouhi, J.M. Geleijnse, G.G. Giles, V. Gudnason, C. Helmer, A. Hodge, R.
398 Jackson, K.-T. Khaw, M. Laakso, H. Lai, D. Laurin, J. Lindsay, R. Micha, J. Mursu, T.
399 Ninomiya, W. Post, B.M. Psaty, U. Riserus, J.G. Robinson, A.H. Shadyab, L. Snetselaar, A.
400 Sala-Vila, Y. Sun, L.M. Steffen, M.Y. Tsai, N.J. Wareham, A.C. Wood, J.H.Y. Wu, F. Hu, Q.
401 Sun, D.S. Siscovick, R.N. Lemaitre, D. Mozaffarian, F. The Fatty Acids and Outcomes
402 Research Consortium, Blood n-3 fatty acid levels and total and cause-specific mortality
403 from 17 prospective studies, *Nature Commun.* 12 (2021) 1–9.
404 <https://doi.org/10.1038/s41467-021-22370-2>.
- 405 [50] S. Kim, M. Eliot, D.C. Koestler, W.-C. Wu, K.T. Kelsey, Association of Neutrophil-to-
406 Lymphocyte Ratio With Mortality and Cardiovascular Disease in the Jackson Heart Study
407 and Modification by the Duffy Antigen Variant, (2018) 8.
- 408 [51] M.A. Zimmerman, Diagnostic Implications of C-Reactive Protein, *Arch Surg.* 138 (2003)
409 220. <https://doi.org/10.1001/archsurg.138.2.220>.
- 410 [52] A. Villaseñor, S.W. Flatt, C. Marinac, L. Natarajan, J.P. Pierce, R.E. Patterson, Postdiagnosis
411 C-Reactive Protein and Breast Cancer Survivorship: Findings from the WHEL Study, *Cancer*
412 *Epidemiol Biomarkers Prev.* 23 (2014) 189–199. [https://doi.org/10.1158/1055-9965.EPI-](https://doi.org/10.1158/1055-9965.EPI-13-0852)
413 13-0852.
- 414 [53] M.L. Knight, The Application of High-Sensitivity C-Reactive Protein in Clinical Practice: A
415 2015 Update, *US Pharmacist.* 40 (2015) 50–53.
- 416 [54] S. Jafarnejad, V. Boccardi, B. Hosseini, M. Taghizadeh, Z. Hamedifard, A Meta-analysis of
417 Randomized Control Trials: The Impact of Vitamin C Supplementation on Serum CRP and

- 418 Serum hs-CRP Concentrations, (2018).
419 <https://doi.org/10.2174/1381612824666181017101810>.
- 420 [55] T.D. Dayspring, S.A. Varvel, L. Ghaedi, D.L. Thiselton, J. Bruton, J.P. McConnell, Biomarkers
421 of cholesterol homeostasis in a clinical laboratory database sample comprising 667,718
422 patients, *Journal of Clinical Lipidology*. 9 (2015) 807–816.
423 <https://doi.org/10.1016/j.jacl.2015.08.003>.
- 424 [56] W.S. Harris, J.V. Pottala, R.S. Vasan, M.G. Larson, S.J. Robins, Changes in erythrocyte
425 membrane trans and marine fatty acids between 1999 and 2006 in older Americans, *J.*
426 *Nutr.* 142 (2012) 1297–1303. <https://doi.org/10.3945/jn.112.158295>.
- 427 [57] WHO, C-reactive protein concentrations as a marker of inflammation or infection for
428 interpreting biomarkers of micronutrient status., World Health Organization, Geneva,
429 Switzerland, 2014.
430 http://apps.who.int/iris/bitstream/10665/133708/1/WHO_NMH_NHD_EPG_14.7_eng.pdf
431 ?ua=1.
- 432 [58] M. Antonelli, I. Kushner, It's time to redefine inflammation, *FASEB J.* 31 (2017) 1787–1791.
433 <https://doi.org/10.1096/fj.201601326R>.
- 434 [59] B. Azab, M. Camacho-Rivera, E. Taioli, Average Values and Racial Differences of Neutrophil
435 Lymphocyte Ratio among a Nationally Representative Sample of United States Subjects,
436 *PLoS ONE*. 9 (2014) e112361. <https://doi.org/10.1371/journal.pone.0112361>.
- 437 [60] J. Li, Q. Chen, X. Luo, J. Hong, K. Pan, X. Lin, X. Liu, L. Zhou, H. Wang, Y. Xu, H. Li, C. Duan,
438 Neutrophil-to-Lymphocyte Ratio Positively Correlates to Age in Healthy Population: NLR

- 439 Correlates to Age, *J. Clin. Lab. Anal.* 29 (2015) 437–443.
- 440 <https://doi.org/10.1002/jcla.21791>.
- 441 [61] Y. Chen, Y. Zhang, G. Zhao, C. Chen, P. Yang, S. Ye, X. Tan, Difference in Leukocyte
442 Composition between Women before and after Menopausal Age, and Distinct Sexual
443 Dimorphism, *PLoS ONE*. 11 (2016) e0162953.
- 444 <https://doi.org/10.1371/journal.pone.0162953>.
- 445 [62] P. Forget, C. Khalifa, J.-P. Defour, D. Latinne, M.-C. Van Pel, M. De Kock, What is the
446 normal value of the neutrophil-to-lymphocyte ratio?, *BMC Res Notes*. 10 (2017) 12.
- 447 <https://doi.org/10.1186/s13104-016-2335-5>.
- 448 [63] J.S. Lee, N.Y. Kim, S.H. Na, Y.H. Youn, C.S. Shin, Reference values of neutrophil-lymphocyte
449 ratio, lymphocyte-monocyte ratio, platelet-lymphocyte ratio, and mean platelet volume in
450 healthy adults in South Korea, *Medicine*. 97 (2018) e11138.
- 451 <https://doi.org/10.1097/MD.00000000000011138>.
- 452 [64] C.P. de Jager, P.T. van Wijk, R.B. Mathoera, J. de Jongh-Leuvenink, T. van der Poll, P.C.
453 Wever, Lymphocytopenia and neutrophil-lymphocyte count ratio predict bacteremia
454 better than conventional infection markers in an emergency care unit, *Crit Care*. 14 (2010)
455 R192. <https://doi.org/10.1186/cc9309>.
- 456 [65] J.C. Yombi, P.E. Schwab, E. Thienpont, Neutrophil-to-lymphocyte ratio (NLR) distribution
457 shows a better kinetic pattern than C-reactive protein distribution for the follow-up of
458 early inflammation after total knee arthroplasty, *Knee Surg Sports Traumatol Arthrosc.* 24
459 (2016) 3287–3292. <https://doi.org/10.1007/s00167-015-3921-0>.

- 460 [66] C. Vors, J. Allaire, J. Marin, M.-C. Lépine, A. Charest, A. Tchernof, P. Couture, B. Lamarche,
461 Inflammatory gene expression in whole blood cells after EPA vs. DHA supplementation:
462 Results from the ComparED study, *Atherosclerosis*. 257 (2017) 116–122.
463 <https://doi.org/10.1016/j.atherosclerosis.2017.01.025>.
- 464 [67] C. Vors, J. Allaire, S.B. Mejia, T.A. Khan, J.L. Sievenpiper, B. Lamarche, Comparing the
465 Effects of Docosahexaenoic and Eicosapentaenoic Acids on Inflammation Markers Using
466 Pairwise and Network Meta-Analyses of Randomized Controlled Trials, *Advances in*
467 *Nutrition*. 12 (2021) 128–140. <https://doi.org/10.1093/advances/nmaa086>.
- 468 [68] S. Weldon, A. Mullen, C. Loscher, L. Hurley, H. Roche, Docosahexaenoic acid induces an
469 anti-inflammatory profile in lipopolysaccharide-stimulated human THP-1 macrophages
470 more effectively than eicosapentaenoic acid, *The Journal of Nutritional Biochemistry*. 18
471 (2007) 250–258. <https://doi.org/10.1016/j.jnutbio.2006.04.003>.
- 472 [69] R. De Caterina, J.K. Liao, P. Libby, Fatty acid modulation of endothelial activation, *The*
473 *American Journal of Clinical Nutrition*. 71 (2000) 213S–223S.
474 <https://doi.org/10.1093/ajcn/71.1.213S>.
- 475 [70] E.M. Balk, A.H. Lichtenstein, M. Chung, B. Kupelnick, P. Chew, J. Lau, Effects of omega-3
476 fatty acids on serum markers of cardiovascular disease risk: A systematic review,
477 *Atherosclerosis*. 189 (2006) 19–30. <https://doi.org/10.1016/j.atherosclerosis.2006.02.012>.
- 478 [71] W. Xin, W. Wei, X. Li, Effects of fish oil supplementation on inflammatory markers in
479 chronic heart failure: a meta-analysis of randomized controlled trials, *BMC Cardiovasc*
480 *Disord*. 12 (2012) 77. <https://doi.org/10.1186/1471-2261-12-77>.

- 481 [72] K. Li, T. Huang, J. Zheng, K. Wu, D. Li, Effect of Marine-Derived n-3 Polyunsaturated Fatty
482 Acids on C-Reactive Protein, Interleukin 6 and Tumor Necrosis Factor α : A Meta-Analysis,
483 PLoS ONE. 9 (2014) e88103. <https://doi.org/10.1371/journal.pone.0088103>.
- 484 [73] S. AbuMweis, S. Jew, R. Tayyem, L. Agraib, Eicosapentaenoic acid and docosahexaenoic
485 acid containing supplements modulate risk factors for cardiovascular disease: a meta-
486 analysis of randomised placebo-control human clinical trials, Journal of Human Nutrition
487 and Dietetics. (2017). <https://doi.org/10.1111/jhn.12493>.
- 488 [74] J.K. Kiecolt-Glaser, M.A. Belury, R. Andridge, W.B. Malarkey, B.S. Hwang, R. Glaser, Omega-
489 3 supplementation lowers inflammation in healthy middle-aged and older adults: A
490 randomized controlled trial | Elsevier Enhanced Reader, Brain, Behav. Immun. 26 (2012)
491 988–995. <https://doi.org/10.1016/j.bbi.2012.05.011>.
- 492 [75] S. Tani, R. Matsuo, W. Atsumi, K. Kawauchi, T. Ashida, T. Yagi, K. Imatake, Y. Suzuki, A.
493 Takahashi, N. Matsumoto, Y. Okumura, Higher Frequency of Fish Intake May Be Associated
494 with a Lower Neutrophil/Lymphocyte Ratio: Anti-Atherosclerotic Effects of Fish
495 Consumption, Ann Nutr Metab. (2021) 1–8. <https://doi.org/10.1159/000515915>.
- 496 [76] A. Sut, K. Chizyński, M. Różalski, J. Golański, Dietary intake of omega fatty acids and
497 polyphenols and its relationship with the levels of inflammatory markers in men with
498 chronic coronary syndrome after percutaneous coronary intervention, Kardiol Pol. 78
499 (2020) 117–123. <https://doi.org/10.33963/KP.15078>.
- 500 [77] J. Jiang, K. Li, F. Wang, B. Yang, Y. Fu, J. Zheng, D. Li, Effect of Marine-Derived n-3
501 Polyunsaturated Fatty Acids on Major Eicosanoids: A Systematic Review and Meta-Analysis

502 from 18 Randomized Controlled Trials, PLoS One. 11 (2016).
503 <https://doi.org/10.1371/journal.pone.0147351>.

504 [78] I. Kushner, D. Rzewnicki, D. Samols, What Does Minor Elevation of C-Reactive Protein
505 Signify?, The American Journal of Medicine. 119 (2006) 166.e17-166.e28.
506 <https://doi.org/10.1016/j.amjmed.2005.06.057>.

507 [79] R. Murphy, E. Yu, E. Ciappio, S. Mehta, M. McBurney, Suboptimal Plasma Long Chain n-3
508 Concentrations are Common among Adults in the United States, NHANES 2003–2004,
509 Nutrients. 7 (2015) 10282–10289. <https://doi.org/10.3390/nu7125534>.

510 [80] R.A. Murphy, P.P. Devarshi, S. Ekimura, K. Marshall, S. Hazels Mitmesser, Long-chain
511 omega-3 fatty acid serum concentrations across life stages in the USA: an analysis of
512 NHANES 2011–2012, BMJ Open. 11 (2021) e043301. [https://doi.org/10.1136/bmjopen-](https://doi.org/10.1136/bmjopen-2020-043301)
513 [2020-043301](https://doi.org/10.1136/bmjopen-2020-043301).

514 [81] W.S. Harris, The Omega-3 Index: Clinical Utility for Therapeutic Intervention, Curr Cardiol
515 Rep. 12 (2010) 503–508. <https://doi.org/10.1007/s11886-010-0141-6>.

516
517

Table 1. Characteristics of the study population. Mean±SD				
Variable ¹	All (n=28,871)	Males (n=14,211)	Females (n=14,660)	Male vs. Female Adjusted ² p-value
O3I (%)	4.97±1.84	4.9±1.82	5.05±1.85	0.016
NLR	2.09±1.10	2.13±1.13	2.05±1.07	<0.0001
Neutrophil (10 ³ /μL)	3.41 ±1.4	3.46±1.4	3.37±1.39	0.0002
Lymphocyte (10 ³ /μL)	1.81±1.47	1.82±1.77	1.80±1.10	<0.0001
CRP (mg/L)	1.23±0.77	1.21±0.75	1.25±0.79	0.0001
BMI (kg/m ²)	27.6±5.4	28.8±4.9	26.6±5.6	0.54
Age (years)	55.1±15.1	55.3±14.7	54.9±15.5	<0.001
¹ O3I, Omega-3 index; NLR, neutrophil-lymphocyte ratio; CRP, high-sensitivity C-reactive protein; BMI, body mass index. ² Models were adjusted for age, BMI, and CRP (except when the model was predicting these variables).				

518

519

520

Table 2. Stratification by omega-3 index (O3I) classification (n=28,871). Mean±SD			
Variable ¹	O3I <6.6% (n=23,510)	O3I ≥6.6% (n=5,361)	Adjusted ² p-value
O3I (%)	4.28±1.11	8.03±1.16	<0.0001
NLR	2.12±1.11	1.96±1.07	<0.0001
Neutrophil (10 ³ /μL)	3.48±1.40	3.11±1.35	<0.0001
Lymphocyte (10 ³ /μL)	1.82±1.56	1.76±0.95	0.591
CRP (mg/L)	1.27±0.78	1.07±0.73	<0.0001
BMI (kg/m ²)	28.0±5.4	26.3±4.9	<0.0001
Age (years)	54.1±15.4	59.4±13.1	<0.0001
¹ O3I, Omega-3 index; NLR, neutrophil-lymphocyte ratio; CRP, high-sensitivity C-reactive protein; BMI, body mass index.			
² Models were adjusted for sex, age, BMI, and CRP (except when the model was predicting these variables).			

521

522

523

524 Figure 1. Analytical sample flow. NLR, neutrophil-lymphocyte ratio; O3I, omega-3 index; CRP,
525 high-sensitivity C-reactive protein; BMI, body mass index.

526

527 Figure 2. The unadjusted (A) and adjusted for sex, age, BMI, and CRP (B) relationship between
528 the neutrophil-lymphocyte ration (NLR) and the omega-3 index (O3I) in 28,871 healthy adults.
529 (Means and 95% confidence bands).



